CHEMOMAB THERAPEUTICS LTD's ticker is CMMB and the CUSIP is 16385C104. A total of 16 filers reported holding CHEMOMAB THERAPEUTICS LTD in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $458 | -50.3% | 288,169 | 0.0% | 0.03% | -51.6% |
| Q4 2022 | $922 | -99.9% | 288,169 | 0.0% | 0.06% | +24.0% |
| Q3 2022 | $718,000 | -32.6% | 288,169 | +0.0% | 0.05% | -38.3% |
| Q2 2022 | $1,066,000 | -22.9% | 288,168 | 0.0% | 0.08% | -23.6% |
| Q1 2022 | $1,383,000 | – | 288,168 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,578,174 | $74,019,000 | 0.69% |
| CVI Holdings, LLC | 93,750 | $2,692,000 | 0.19% |
| Maven Securities LTD | 126,562 | $3,634,000 | 0.16% |
| BOOTHBAY FUND MANAGEMENT, LLC | 61,761 | $1,773,000 | 0.07% |
| MEITAV INVESTMENT HOUSE LTD | 8,311 | $239,000 | 0.01% |
| Ironwood Financial, llc | 167 | $5,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 76 | $2,000 | 0.00% |
| Renaissance Technologies | 7,023 | $202,000 | 0.00% |
| UBS Group AG | 834 | $24,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |